CU23241B7 - 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos - Google Patents

2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos

Info

Publication number
CU23241B7
CU23241B7 CU20000255A CU20000255A CU23241B7 CU 23241 B7 CU23241 B7 CU 23241B7 CU 20000255 A CU20000255 A CU 20000255A CU 20000255 A CU20000255 A CU 20000255A CU 23241 B7 CU23241 B7 CU 23241B7
Authority
CU
Cuba
Prior art keywords
phenyl
aminoetoxi
strogens
benzil
indol
Prior art date
Application number
CU20000255A
Other languages
English (en)
Inventor
Barry Samuel Komm
James Harrison Pickar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23241(B7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CU23241B7 publication Critical patent/CU23241B7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con nuevas formulaciones que contienen uno o mAs estrogenos y compuestos 2-fenil-1-(4-(2-aminoetoxi)bencil)-indol los cuales son Utiles como agentes estrogÉnicos, así como composiciones farmacÉuticas y mÉtodos de tratamiento que utilizan estos compuestos, que tienen las estructuras generales ( I ) o ( II ).
CU20000255A 1998-05-15 2000-11-15 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos CU23241B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956198A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
CU23241B7 true CU23241B7 (es) 2007-10-17

Family

ID=22151320

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000255A CU23241B7 (es) 1998-05-15 2000-11-15 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos

Country Status (42)

Country Link
EP (1) EP1076558B1 (es)
JP (3) JP2002515431A (es)
KR (1) KR100620772B1 (es)
CN (1) CN1230163C (es)
AP (1) AP1424A (es)
AR (1) AR020074A1 (es)
AT (1) ATE245026T1 (es)
AU (1) AU760378B2 (es)
BE (1) BE2015C026I2 (es)
BG (1) BG64783B1 (es)
BR (1) BR9911040A (es)
CA (1) CA2329530A1 (es)
CU (1) CU23241B7 (es)
CY (1) CY2015020I1 (es)
CZ (1) CZ299334B6 (es)
DE (1) DE69909616T2 (es)
DK (1) DK1076558T3 (es)
EA (1) EA005932B1 (es)
EE (1) EE04262B1 (es)
ES (1) ES2203131T3 (es)
FR (1) FR15C0035I2 (es)
GE (1) GEP20033079B (es)
HK (1) HK1031691A1 (es)
HR (1) HRP20000778B1 (es)
HU (2) HU226587B1 (es)
ID (1) ID26890A (es)
IL (1) IL139130A (es)
IN (1) IN192220B (es)
LT (1) LTC1076558I2 (es)
LU (1) LU92699I2 (es)
NO (2) NO328129B1 (es)
NZ (1) NZ508200A (es)
OA (1) OA11552A (es)
PL (1) PL194750B1 (es)
PT (1) PT1076558E (es)
SI (1) SI1076558T1 (es)
SK (1) SK284666B6 (es)
TR (1) TR200003377T2 (es)
TW (1) TW565554B (es)
UA (1) UA66861C2 (es)
WO (1) WO1999059581A1 (es)
ZA (1) ZA200006959B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284666B6 (sk) * 1998-05-15 2005-08-04 Wyeth Farmaceutický prostriedok obsahujúci indolové zlúčeniny a estrogény a jeho použitie
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN1390126B (zh) 1999-07-06 2012-06-13 恩多研究公司 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
EP1299093A2 (en) * 2000-07-06 2003-04-09 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
CN1468110A (zh) * 2000-07-06 2004-01-14 惠氏公司 他汀类、雌激素药物以及任选雌激素的联合应用
DE10117441A1 (de) * 2001-04-03 2002-10-10 Schering Ag 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
KR100470274B1 (ko) 2002-11-08 2005-02-05 진 장 덮개층을 이용한 비정질 물질의 상 변화 방법
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5635493B2 (ja) 2008-04-16 2014-12-03 カロ バイオ アクチェブラーグ 新規エストロゲン受容体リガンド
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
CN103709090A (zh) * 2014-01-16 2014-04-09 江苏万特制药有限公司 醋酸巴多昔芬的制备方法及其关键中间体
CN103739540B (zh) * 2014-01-20 2016-05-04 华润赛科药业有限责任公司 一种醋酸巴多昔芬中间体的制备方法
CN105669518B (zh) * 2014-12-04 2019-06-04 上海医药集团股份有限公司 醋酸巴多昔芬及其a晶型的制备方法
KR20200100687A (ko) 2017-12-15 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. PROTEOLYSIS REGULATOR AND METHOD OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
CA2135160A1 (en) * 1992-05-08 1993-11-25 Masatoshi Inai Indole derivative
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP0802183B1 (en) * 1996-04-19 2001-10-10 American Home Products Corporation Estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
IL127668A0 (en) * 1996-07-09 1999-10-28 Smithkline Beecham Spa Indole derivatives for the treatment of osteoporosis
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CN1231458C (zh) * 1997-10-15 2005-12-14 惠氏公司 新的芳氧基－烷基－二烷基胺类化合物
AU1197299A (en) * 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
SK284666B6 (sk) * 1998-05-15 2005-08-04 Wyeth Farmaceutický prostriedok obsahujúci indolové zlúčeniny a estrogény a jeho použitie

Also Published As

Publication number Publication date
SK284666B6 (sk) 2005-08-04
BE2015C026I2 (en) 2018-08-24
EE200000652A (et) 2002-04-15
BG64783B1 (bg) 2006-04-28
NO20005770D0 (no) 2000-11-14
HRP20000778A2 (en) 2001-06-30
HUS1500023I1 (hu) 2017-03-28
OA11552A (en) 2004-06-07
KR100620772B1 (ko) 2006-09-13
ATE245026T1 (de) 2003-08-15
EP1076558A1 (en) 2001-02-21
JP2002515431A (ja) 2002-05-28
HUP0103096A3 (en) 2002-11-28
FR15C0035I1 (es) 2015-06-26
PL194750B1 (pl) 2007-06-29
UA66861C2 (uk) 2004-06-15
NO20005770L (no) 2001-01-12
WO1999059581A1 (en) 1999-11-25
JP2014159472A (ja) 2014-09-04
DK1076558T3 (da) 2003-11-03
JP5607871B2 (ja) 2014-10-15
NO2015015I2 (no) 2015-06-02
KR20010043641A (ko) 2001-05-25
ZA200006959B (en) 2001-11-27
TW565554B (en) 2003-12-11
IL139130A0 (en) 2001-11-25
LTC1076558I2 (lt) 2016-11-10
ID26890A (id) 2001-02-15
AU760378B2 (en) 2003-05-15
DE69909616D1 (de) 2003-08-21
HU226587B1 (en) 2009-04-28
EA200001193A1 (ru) 2001-12-24
HRP20000778B1 (en) 2004-10-31
PL345268A1 (en) 2001-12-03
ES2203131T3 (es) 2004-04-01
LU92699I2 (fr) 2015-06-24
GEP20033079B (en) 2003-10-27
HK1031691A1 (en) 2001-06-22
HUP0103096A2 (hu) 2002-05-29
DE69909616T2 (de) 2004-06-17
AR020074A1 (es) 2002-04-10
BR9911040A (pt) 2001-02-13
SK17202000A3 (sk) 2001-07-10
TR200003377T2 (tr) 2001-03-21
BG104930A (en) 2001-07-31
JP5872624B2 (ja) 2016-03-01
IN192220B (es) 2004-03-20
EA005932B1 (ru) 2005-08-25
NO2015015I1 (no) 2015-06-02
SI1076558T1 (en) 2003-10-31
EE04262B1 (et) 2004-04-15
AP1424A (en) 2005-06-06
EP1076558B1 (en) 2003-07-16
CY2015020I1 (el) 2020-05-29
CN1230163C (zh) 2005-12-07
PT1076558E (pt) 2003-11-28
FR15C0035I2 (fr) 2015-08-28
AU3894499A (en) 1999-12-06
CZ20004254A3 (cs) 2001-12-12
CZ299334B6 (cs) 2008-06-25
CA2329530A1 (en) 1999-11-25
JP2009019042A (ja) 2009-01-29
NO328129B1 (no) 2009-12-14
NZ508200A (en) 2003-09-26
CN1326347A (zh) 2001-12-12
AP2000001970A0 (en) 2000-12-31
IL139130A (en) 2005-11-20

Similar Documents

Publication Publication Date Title
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
AR019503A1 (es) Utilizacion de derivados sustituidos en 3 del estilbeno como agentes activos desodorantes en las composiciones cosmeticas
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
DE69939661D1 (de) Hautdesodorierende und desinfizierende zubereitung
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ES2079589T3 (es) Agentes farmaceuticos.
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
AR028948A1 (es) Compuestos novedosos
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
IS6520A (is) Ný efnasambönd
MX9702865A (es) Agentes estrogenicos.
ES2113127T3 (es) Derivado de androstenona.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
YU7797A (sh) Kombinovana terapija za osteoporozu
ES2195189T3 (es) Benzonaftiridinas como agentes terapeuticos bronquiales.
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
PT889886E (pt) Novas fenantridinas substituidas na posicao 6
CO5080743A1 (es) Benzocicloheptenos, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen. .
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
GT200100153A (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradiquinina.
GT199800106A (es) Azetidinas.
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2157524T3 (es) Diselenuros y selenosulfuros utilizables como agentes antioxidantes.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)